MX346533B - Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides). - Google Patents

Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).

Info

Publication number
MX346533B
MX346533B MX2013009760A MX2013009760A MX346533B MX 346533 B MX346533 B MX 346533B MX 2013009760 A MX2013009760 A MX 2013009760A MX 2013009760 A MX2013009760 A MX 2013009760A MX 346533 B MX346533 B MX 346533B
Authority
MX
Mexico
Prior art keywords
disease
hyperalgesia
crystalline forms
osteoarthritis
receptor
Prior art date
Application number
MX2013009760A
Other languages
English (en)
Other versions
MX2013009760A (es
Inventor
c blackburn Anthony
Han Sangdon
M Jones Robert
Garrido Montalban Anthony
B Pal Biman
Karyn Rueter Jaimie
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2013009760A publication Critical patent/MX2013009760A/es
Publication of MX346533B publication Critical patent/MX346533B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a formas cristalinas de ((S)-1-hidroximetil-1,2-dimetil-propil)-amida de ácido (1aS,5aS)-2-(4-oxi-pirazin-2-il)-1a,2,5,5a-tetrahidro-1H-2,3-diaz a-ciclopropa[a}pentalen-4- carboxílico y composiciones farmacéutica de la misma que modulan la actividad del receptor canabinoide CB2 y por lo tanto son útiles en el tratamiento de desórdenes mediados por receptor CB2, por ejemplo, osteoartritis; dolor; hiperalgesia; alodinia; hiperalgesia inflamatoria; hiperalgesia neuropática, nocicepción aguda; osteoporosis; espasticidad asociada con esclerosis múltiple; desórdenes autoinmunes; reacciones alérgicas inflamación de CNS por ejemplo; aterosclerosis; actividad celular inmune no deseada, e inflamación asociada con un desorden seleccionado de: osteoartritis, anafilaxis, enfermedad de Behcet, rechazo de injerto, vasculitis, gota, espondilitis, enfermedad viral, enfermedad bacteriana, lupus, enfermedad inflamatoria intestinal, hepatitis autoinmune y diabetes mellitus tipo 1; degeneración macular relacionada con la edad; tos; leucemia; linfoma; tumores de GNS; cáncer de próstata; enfermedad de Alzheimer; daño inducido por apoplejía; demencia; esclerosis lateral amiotrófica; y enfermedad de Parkinson.
MX2013009760A 2011-02-25 2012-02-24 Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides). MX346533B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US201161448542P 2011-03-02 2011-03-02
PCT/US2012/026506 WO2012116276A1 (en) 2011-02-25 2012-02-24 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Publications (2)

Publication Number Publication Date
MX2013009760A MX2013009760A (es) 2014-06-11
MX346533B true MX346533B (es) 2017-03-14

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009760A MX346533B (es) 2011-02-25 2012-02-24 Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).

Country Status (19)

Country Link
US (4) US9458136B2 (es)
EP (3) EP2678330A1 (es)
JP (1) JP5945554B2 (es)
KR (1) KR102036932B1 (es)
CN (1) CN103608343B (es)
AU (1) AU2012222146B2 (es)
BR (1) BR112013021549B1 (es)
CA (1) CA2827057C (es)
CL (1) CL2013002436A1 (es)
CO (1) CO6852066A2 (es)
DK (1) DK3395812T3 (es)
EA (1) EA035989B1 (es)
ES (1) ES2932441T3 (es)
IL (1) IL227782A (es)
MX (1) MX346533B (es)
MY (1) MY165767A (es)
SG (1) SG192817A1 (es)
WO (1) WO2012116276A1 (es)
ZA (1) ZA201306402B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200008045A (ko) 2009-08-28 2020-01-22 아레나 파마슈티칼스, 인크. 칸나비노이드 수용체 조절제
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
MX346644B (es) 2011-02-25 2017-03-14 Arena Pharm Inc Moduladores de receptores canabinoides.
EP2678330A1 (en) * 2011-02-25 2014-01-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
UA124626C2 (uk) * 2016-04-10 2021-10-20 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СЕЛЕКТИВНИМИ АГОНІСТАМИ РЕЦЕПТОРА СВ<sub>2</sub>
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
KR20200005614A (ko) * 2017-05-08 2020-01-15 아레나 파마슈티칼스, 인크. 내장 통증의 치료를 위한 화합물 및 방법
CN114391011A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
TW202330496A (zh) 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
CA2468794A1 (en) 2001-12-07 2003-06-19 Virginia Commonwealth University Treatment of neoplasia
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
KR20070041717A (ko) 2004-07-12 2007-04-19 카딜라 핼쓰캐어 리미티드 카나비노이드 수용체 조절자인 트리시클릭 피라졸 유도체들
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
UA93390C2 (ru) * 2005-06-02 2011-02-10 Гленмарк Фармасьютикалс C.A. Лиганды каннабиноидных рецепторов, фармацевтическая композиция (варианты), которая их содержит, и способ их получения
JP2008545739A (ja) * 2005-06-02 2008-12-18 グレンマーク・ファーマシューティカルズ・エスエー 新規なカンナビノイド受容体リガンド、それらを含む薬剤組成物、およびそれらの調製方法
CA2654246A1 (en) 2006-07-04 2008-01-10 Janssen Pharmaceutica N.V. Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2008063781A2 (en) 2006-10-12 2008-05-29 Abbott Laboratories Chemical compounds as cannabinoid receptor ligands
US7928103B2 (en) 2006-10-17 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
AU2007315848A1 (en) 2006-11-03 2008-05-08 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
US20090325936A1 (en) 2006-12-20 2009-12-31 Bilodeau Mark T Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080214537A1 (en) 2007-03-02 2008-09-04 Cara Therapeutics, Inc. Bridged phenanthridines
WO2008114619A1 (ja) 2007-03-16 2008-09-25 Kyocera Corporation 誘電体磁器およびコンデンサ
WO2008119694A1 (en) 2007-03-30 2008-10-09 Janssen Pharmaceutica Nv Benzimidazole cannabinoid agonists
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
ES2439255T3 (es) 2007-06-21 2014-01-22 Cara Therapeutics, Inc. Imidazoheterociclos sustituidos
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
WO2009025785A2 (en) 2007-08-21 2009-02-26 Merck & Co., Inc. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
WO2010088050A2 (en) 2009-01-28 2010-08-05 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
KR20200008045A (ko) 2009-08-28 2020-01-22 아레나 파마슈티칼스, 인크. 칸나비노이드 수용체 조절제
EP2678330A1 (en) * 2011-02-25 2014-01-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
MX346644B (es) * 2011-02-25 2017-03-14 Arena Pharm Inc Moduladores de receptores canabinoides.

Also Published As

Publication number Publication date
MX2013009760A (es) 2014-06-11
US10183930B2 (en) 2019-01-22
EA035989B1 (ru) 2020-09-09
CA2827057C (en) 2022-06-07
EA201391233A1 (ru) 2014-02-28
US11560369B2 (en) 2023-01-24
BR112013021549B1 (pt) 2022-01-11
CN103608343B (zh) 2019-02-01
JP5945554B2 (ja) 2016-07-05
CO6852066A2 (es) 2014-01-30
US9458136B2 (en) 2016-10-04
AU2012222146A1 (en) 2013-09-19
NZ614787A (en) 2014-08-29
AU2012222146B2 (en) 2017-05-11
ES2932441T3 (es) 2023-01-19
KR102036932B1 (ko) 2019-10-25
CN103608343A (zh) 2014-02-26
ZA201306402B (en) 2022-03-30
EP3395812B1 (en) 2022-09-28
KR20140025353A (ko) 2014-03-04
IL227782A0 (en) 2013-09-30
US20140135345A1 (en) 2014-05-15
EP2678330A1 (en) 2014-01-01
EP3395812A1 (en) 2018-10-31
JP2014506602A (ja) 2014-03-17
BR112013021549A2 (pt) 2016-11-01
DK3395812T3 (da) 2022-11-28
EP3395812B8 (en) 2022-11-02
IL227782A (en) 2017-02-28
SG192817A1 (en) 2013-09-30
EP4166552A1 (en) 2023-04-19
US10981895B2 (en) 2021-04-20
CL2013002436A1 (es) 2014-01-24
US20190308952A1 (en) 2019-10-10
WO2012116276A1 (en) 2012-08-30
US20170144993A1 (en) 2017-05-25
MY165767A (en) 2018-04-23
CA2827057A1 (en) 2012-08-30
US20210380560A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
MX346533B (es) Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).
ZA202205142B (en) Cannabinoid receptor modulators
WO2008155534A3 (en) Neurosteroid compounds
WO2011075534A3 (en) Purification of isoprene from renewable resources
AU2011343222B2 (en) Novel 7B-hydroxysteroid dehydrogenase mutants and process for the preparation of ursodeoxycholic acid
JP2013533314A5 (es)
WO2012054616A3 (en) Synthesis of methylene malonates substantially free of impurities
WO2013060614A9 (de) Farbstabile härterzusammensetzungen enthaltend polyisocyanate (cyclo)aliphatischer diisocyanate
BR112012019156A2 (pt) processo para recuperação de etanol
WO2012173659A3 (en) Lignocellulosic hydrolysates as feedstocks for isobutanol fermentation
WO2011139107A3 (en) Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and phamaceutical composition comprising the same
MX2013007667A (es) Procesos y sistemas para aislar enzimaticamente lignina y otros bioproductos de plantas herbaceas.
WO2012104244A8 (de) Verfahren zur fermentativen herstellung von 2,3-butandiol
MX2012004559A (es) Metodos y sistemas para tratamiento farmacogenomico de condiciones cardiovasculares.
WO2012045022A3 (en) Metabolic engineering of clostridium tyrobutyricum for butanol production
IN2014MN01003A (es)
WO2012013454A8 (de) Verfahren zur verminderung von magnetischen und/oder oxidischen verunreinigungen in lithium-metall-sauerstoff-verbindungen
NZ703093A (en) Purification of iduronate-2-sulfatase
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
EP2384756A3 (en) High-purity large-scale preparation of stannsoporfin
WO2010066680A3 (de) Verfahren zur abtrennung metallischer verunreinigungen
MX2014005561A (es) Suavizante de telas.
WO2010090536A3 (en) Plant transformation using dna minicircles
IL231490B (en) A viral vector containing a plant DNA sequence (codon-optimized) and a method for the temporary production of cholinesterase using this vector
WO2013072592A3 (fr) Épaississants non ioniques associatifs contenant des alkyls cyclohexylols alkoxyles, leurs utilisations et formulations les contenant

Legal Events

Date Code Title Description
FG Grant or registration